Aurisco Expands Oligonucleotide Capacity

Aurisco Pharmaceutical, a pharmaceutical contract research, development and manufacturing organization (CRDMO) expanded its oligonucleotide manufacturing capacity.

The new OligoPilot 2000TM solid-phase synthesizer, from Cytiva, completes Aurisco Biotech’s pilot scale cGMP plant and provides immediate capacity availability to accelerate customer’s clinical programs as well as Aurisco’s generic oligonucleotide pipeline.

Peng Zhien, chairman of Aurisco, said: “The company is committed to continuous technological innovation, such as solid-phase synthesis, chromatography, photochemistry and biocatalysis. Our strong R&D, state-of-art analytical tools, advanced manufacturing capabilities and project management experience will help our customers deliver faster, better, safer and more affordable medicines to patients around the world. We’ve joined Manufacture 2030, Energize and Ecovadis in a true commitment to sustainability and reduce the carbon footprint of pharmaceutical supply-chains. We pay special attention to ESG and Supply-Chain Security topics.”